Arbutus Biopharma Corporation
ABUS
$4.44
$0.010.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.74M | 2.52M | -24.53M | -12.53M | -19.72M |
| Total Depreciation and Amortization | 11.00K | 11.00K | 330.00K | 333.00K | 336.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 764.00K | -43.00K | 5.54M | 2.11M | 1.14M |
| Change in Net Operating Assets | 1.15M | -18.24M | 5.27M | -229.00K | -2.50M |
| Cash from Operations | -5.82M | -15.75M | -13.39M | -10.32M | -20.74M |
| Capital Expenditure | -- | -- | -- | -86.00K | 0.00 |
| Sale of Property, Plant, and Equipment | 0.00 | 9.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -10.02M | 15.60M | 11.35M | 13.50M | -11.99M |
| Cash from Investing | -10.02M | 15.61M | 11.35M | 13.41M | -11.99M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 844.00K | 453.00K | 2.78M | 1.42M | 1.78M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 844.00K | 453.00K | 2.78M | 1.42M | 1.78M |
| Foreign Exchange rate Adjustments | -12.00K | 21.00K | 4.00K | -33.00K | 5.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.00M | 336.00K | 746.00K | 4.48M | -30.94M |